Experienced biotechnology expert joins BRAIN Biotech AG's Supervisory Board EQS News: BRAIN Biotech AG / Key word(s): Personnel Experienced biotechnology expert joins BRAIN Biotech AG's Supervisory Board 23.07.2025 / 08:30 CET/CEST Responsible for the ...
EQS News: Experienced biotechnology expert joins the Supervisory Board of BRAIN Biotech AG (German)
Experienced biotechnology expert joins the Supervisory Board of BRAIN Biotech AG
EQS News: BRAIN Biotech AG / Key word(s): Personnel Experienced biotechnology expert joins the Supervisory Board of BRAIN Biotech AG 23.07.2025 / 08:30 CET/CEST The issuer/publisher is responsible for the content of this announcement. --------------------------------------------------------------------------- Experienced biotechnology expert joins the Supervisory Board of BRAIN Biotech AG ZWINGENBERG, July 23, 2025 - The Supervisory Board of BRAIN Biotech AG is fully staffed again: Dr. Ursula La Cognata was appointed by the District Court Darmstadt with effect from 11 July 2025 until the next Annual General Meeting as a new member of the Supervisory Board. With her many years of biotechnology experience, the now complete six-member committee. Dr. Ursula La Cognata has held leading positions for many years for Companies with a strong biotechnology focus, including Aventis and Bayer and most recently with a focus on enzymes, fermentation and natural foods. Dr. La Cognata currently leads her own consulting company and supports innovative companies in the market launch in the food sector and the development of Production and fermentation capacities. Chairman of the Supervisory Board Dr. Michael Majerus explains: "We have discussed with Ms. Dr. Ursula La Cognata for our Supervisory Board a scientifically and to recruit a highly competent and experienced biotechnologist who, in addition to their extensive industry experience in connection with Enzymes and fermentation processes, including their expertise in product development and market launch of innovations. We warmly welcome the new Supervisory Board member and are very pleased on the constructive cooperation with her." Adriaan Moelker, CEO of BRAIN Biotech AG, adds: "I am very pleased about the extensive biotechnology expertise of our new Supervisory Board member. We gain a lot of experience and networks in our Target markets: nutrition, life sciences and the environment." The judicial appointment of a new member to the Supervisory Board was became necessary after a member of the Supervisory Board resigned from her mandate for personal reasons. reasons. +++ BRAIN Biotech Group The BRAIN Biotech Group is a leading company in the research, Development and production of special enzymes with a focus on Food and life science industries. In addition, the Group of microbial production organisms and scalable Bioprocesses for the economical production of specialty enzymes and other proteins. Tailor-made innovative biological solutions for More sustainable products and processes complete the offering. The parent company of the BRAIN Biotech Group is BRAIN Biotech AG. The business activities of the integrated company are divided into both segments BRAINBiocatalysts (development, production and distribution of Special enzymes, microorganisms, ingredients) and BRAINBioIncubator (research-intensive development projects, pharmaceuticals). For production The Group operates fermentation plants in Great Britain and plants in Continental Europe and the USA. BRAIN Biotech has been listed on the Frankfurt Stock Exchange since February 9, 2016. Stock Exchange (Ticker: BNN; ISIN DE0005203947 / WKN 520394). The company employs around 300 people at several locations and achieved sales of EUR 54.6 million in the 2023/24 financial year. Further Information at: www.brain-biotech-group.com. Contact Investor Relations Martina Schuster Investor Relations Phone: +49 6251 9331-69 Email: [email protected] Contact Media Dr. Stephanie Konle PR & Corporate Communications Phone: +49 6251 9331-70 Email: [email protected] The BRAIN Biotech Group on social media and online: BRAIN Biotech Group Web: www.brain-biotech-group.com LinkedIn: https://www.linkedin.com/company/brainbiotech Threads: https://www.threads.net/@brainbiotechag Bluesky: https://bsky.app/profile/brain-biotech-group.com X: https://x.com/BRAINbiotech Youtube: https://www.youtube.com/channel/UCS33HJqku674X22UQ8QIsyg Biocatalysts Ltd (production, distribution) Website: https://www.biocatalysts.com/ LinkedIn: Biocatalysts Ltd on LinkedIn / BRAIN-Biocatalysts Life Science Solutions on LinkedIn BRAIN Biotech Zwingenberg (Technologies & Services) Website: www.brain-biotech.com LinkedIn: BRAIN Biotech Technologies & Services AnalyticonDiscovery (Research & Development) Web: https://ac-discovery.com/ LinkedIn: https://www.linkedin.com/company/analyticon-discovery/ Disclaimer This press release contains forward-looking statements. These statements reflect the current views, expectations and assumptions of the Management of BRAIN Biotech AG and are based on information that available to management at the present time. Forward-looking statements do not contain any guarantee of future results and developments and are subject to known and unknown risks and uncertainties. The actual future results of BRAIN Biotech AG and the BRAIN Biotech Group and Developments concerning BRAIN Biotech AG and the BRAIN Biotech Group can therefore differ significantly from the information provided here due to various factors. expectations and assumptions expressed. These factors include in particular changes in the general economic situation and the competitive situation. In addition, developments in the Financial markets and exchange rate fluctuations as well as national and international Changes in the law, particularly with regard to tax regulations, as well as other factors affect future results and Developments by BRAIN Biotech AG. BRAIN Biotech AG assumes no liability for the information contained in this to update the statements contained therein. Note: Collective terms used in this press release such as Employees, shareholders, customers or consumers are considered gender-neutral to watch. --------------------------------------------------------------------------- 23.07.2025 CET/CEST Publication of a corporate news/financial news, transmitted by EQS News - a service of the EQS Group. The issuer/publisher is responsible for the content of this announcement. The EQS Distribution Services include statutory reporting obligations, corporate News/financial news and press releases. Media archive at https://eqs-news.com --------------------------------------------------------------------------- Language: German Company: BRAIN Biotech AG Darmstadter Straße 34-36 64673 Zwingenberg Germany Telephone: +49 (0) 62 51 / 9331-0 Fax: +49 (0) 62 51 / 9331-11 Email: [email protected] Internet: www.brain-biotech.com ISIN: DE0005203947 WKN: 520394 Stock exchanges: Regulated market in Frankfurt (Prime Standard); Over-the-counter in Berlin, Düsseldorf, Hamburg, Munich, Stuttgart, Tradegate Exchange EQS News ID: 2173240 End of message EQS News Service --------------------------------------------------------------------------- 2173240 23.07.2025 CET/CEST
ad-hoc-news
